Bayer

The Bayer GroupBayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.

www.bayer.com.

Bayer RSS Channel

Display # 
Title Published Date
Bayer Science & Education Foundation launches new round of funding 08 June 2016
Grants4Apps Accelerator 2016: You imagine, Bayer supports 10 May 2016
Bayer off to a successful start in 2016 26 April 2016
2016 Otto Bayer Award goes to Professor Dr. Dirk Trauner 25 April 2016
Bayer continues to grow its open innovation activities 09 February 2016
Bayer halves the price of its contraceptive implant Jadelle® for women in developing countries 08 January 2016
Bayer and CRISPR Therapeutics AG join forces to discover, develop and commercialize potential cures for serious genetic diseases 21 December 2015
Bayer's new five-year-contraceptive submitted for EU and US marketing authorization 20 November 2015
Bayer aligns organization with Life Science businesses 18 September 2015
New scholarships worth EUR 332,000 awarded by Bayer Foundation to promote international talents 16 September 2015
Bayer significantly improves earnings 29 July 2015
Bayer to divest Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd. for EUR 1,022 million 10 June 2015
Xarelto® approved in China across three indications in the area of venous and arterial thromboembolism 07 May 2015
Strong start to the year for Bayer 30 April 2015
Bayer aspires to significantly expand Life Science businesses 11 March 2015
Bayer forms collaboration with academic and governmental institutions for Rivaroxaban study 10 February 2015
Bayer operationally strong - strategic focus on Life Science businesses 02 November 2014
Bayer supports World Thrombosis Day as founding global partner 13 October 2014
Bayer closes acquisition of consumer care business of Merck & Co., Inc., United States, for USD 14.2 billion 01 October 2014
Safety and sustained benefits of Adempas® from Bayer confirmed by results of long-term studies 08 September 2014

Most Popular Now

Novo Nordisk and Aarhus University …

Novo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Unde...

Read more

AstraZeneca enters licensing agreem…

AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation and Autoimmunity, ...

Read more

Bristol-Myers Squibb acquires Cormo…

Bristol-Myers Squibb Company (NYSE:BMY) and Cormorant Pharmaceuticals announced today that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormo...

Read more

Bristol-Myers Squibb and PsiOxus Th…

Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, to...

Read more

Sanofi Pasteur signs research agree…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Resear...

Read more

FDA advances Precision Medicine Ini…

In support of the President’s Precision Medicine Initiative, the U.S. Food and Drug Administration has issued two draft guidances that, when finalized, will provide a fle...

Read more

Merck and Pfizer initiate Phase III…

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) have announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of ave...

Read more

Twisting and turning to target anti…

Researchers are getting closer to understanding how some natural antibiotics work so they can develop drugs that mimic them. A recent review commissioned by the British g...

Read more

Merck commits €1.5 million to the G…

Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Gra...

Read more

FDA approves first and only single …

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) PushtronexTM system (on-body infusor with pref...

Read more

A 'big data' approach to developing…

Scientists are starting to accumulate huge datasets on which genes mutate during cancer, allowing for a more systematic approach to "precision medicine." In a study publi...

Read more

Amgen and Daiichi Sankyo announce a…

Amgen (NASDAQ:AMGN) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo; TSE 4568) today announced the execution of an exclusive agreement to commercialize nin...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016